Evolving Landscape of HR+ Metastatic Breast Cancer Management
Closing out their review of treatment strategies for HR+ metastatic breast cancer, a panel of experts highlights ongoing investigations and future directions in care.
Closing out their review of treatment strategies for HR+ metastatic breast cancer, a panel of experts highlights ongoing investigations and future directions in care.
Those who have been previously treated for KRAS G12C–mutated advanced NSCLC may benefit from treatment with glecirasib.
Findings from the phase 3 DESTINY-Breast06 trial will be presented at a future medical meeting and shared with regulatory authorities.
Tisotumab vedotin-tftv may now be given to patients with recurrent or metastatic cervical cancer, according to the FDA.
Tisotumab vedotin-tftv may now be given to patients with recurrent or metastatic cervical cancer, according to the FDA.
The latest CARTITUDE-4 data examine the efficacy and safety of ciltacabtagene autoleucel in lenalidomide-refractory multiple myeloma.
Patients enrolled across the CARTITUDE trials who experienced cranial nerve palsy after treatment with cilta-cel were generally male.
The FDA approval of the single-agent, oral pan-RAF inhibitor tovorafenib is based on efficacy results from the phase 2 FIREFLY-1 trial.
Increasing screening for younger individuals who are at risk of colorectal cancer may help mitigate the rising early incidence of this disease.
Data from 2 NETTER trials support lutetium Lu 177 dotatate’s approval in somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors.
Investigators of the phase 3 ALINA trial report no unexpected safety findings with alectinib in ALK-positive non–small cell lung cancer.